Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology (Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on targeted therapies for women's cancers, has announced the granting of stock options to two new employees. The options allow the purchase of 11,800 shares of the company's common stock, effective August 1, 2024. These awards were approved by the Compensation Committee and granted under Olema's 2022 Inducement Plan.
The stock options have a 10-year term and an exercise price of $16.46 per share, equal to the last reported sale price on August 1, 2024. They vest over four years, with 25% vesting on the first anniversary and the remainder vesting in 36 equal monthly installments, subject to continuous employment. This grant is in accordance with Nasdaq Listing Rule 5635(c)(4) as an inducement for new employees.
Olema Oncology (Nasdaq: OLMA), un'azienda biofarmaceutica in fase clinica focalizzata su terapie mirate per i tumori femminili, ha annunciato la concessione di opzioni su azioni a due nuovi dipendenti. Le opzioni consentono l'acquisto di 11.800 azioni ordinarie della società, con decorrenza dal 1° agosto 2024. Questi premi sono stati approvati dal Comitato Compensi e concessi nell'ambito del Piano di Incentivazione 2022 di Olema.
Le opzioni hanno un termine di 10 anni e un prezzo di esercizio di $16,46 per azione, pari all'ultimo prezzo di vendita riportato il 1° agosto 2024. Esse si maturano in quattro anni, con il 25% che matura al primo anniversario e il restante in 36 rate mensili uguali, soggetto a mantenimento dell'impiego. Questa concessione è conforme alla Regola di Quotazione Nasdaq 5635(c)(4) come incentivo per i nuovi dipendenti.
Olema Oncology (Nasdaq: OLMA), una empresa biofarmacéutica en etapa clínica centrada en terapias dirigidas para el cáncer de mujeres, ha anunciado la concesión de opciones sobre acciones a dos nuevos empleados. Las opciones permiten la compra de 11,800 acciones comunes de la empresa, efectivas a partir del 1 de agosto de 2024. Estos beneficios fueron aprobados por el Comité de Compensación y otorgados bajo el Plan de Inducción 2022 de Olema.
Las opciones sobre acciones tienen un plazo de 10 años y un precio de ejercicio de $16.46 por acción, igual al último precio de venta informado el 1 de agosto de 2024. Se consolidan en cuatro años, con un 25% que se consolida en el primer aniversario y el resto en 36 cuotas mensuales iguales, sujeto a empleo continuo. Esta concesión cumple con la Regla de Listado 5635(c)(4) de Nasdaq como un incentivo para nuevos empleados.
올레마 온콜로지(Olema Oncology, Nasdaq: OLMA)는 여성 암에 대한 타겟 치료에 중점을 둔 임상 단계의 생명공학 회사로, 두 명의 신규 직원에게 주식 매수 선택권을 부여했다고 발표했습니다. 이 옵션은 2024년 8월 1일부터 회사의 보통주 11,800주를 구매할 수 있도록 허용합니다. 이 상여는 보상위원회의 승인을 받았으며 올레마의 2022 유도 계획에 따라 부여되었습니다.
주식 매수 옵션은 10년의 기간을 가지며, 행사 가격은 주당 $16.46로, 2024년 8월 1일에 보고된 마지막 판매 가격과 동일합니다. 이 옵션은 4년 동안 부여되며, 첫 번째 기념일에 25%가 부여되고 나머지는 36개월 동안 매월 동등하게 분할됩니다. 이 부여는 Nasdaq 상장 규칙 5635(c)(4)에 따라 신규 직원에 대한 유도책으로 실시됩니다.
Olema Oncology (Nasdaq: OLMA), une entreprise biopharmaceutique en phase clinique spécialisée dans les thérapies ciblées pour les cancers féminins, a annoncé l'octroi d'options d'achat d'actions à deux nouveaux employés. Ces options permettent l'achat de 11 800 actions ordinaires de l'entreprise, effectif à partir du 1er août 2024. Ces récompenses ont été approuvées par le Comité de rémunération et accordées dans le cadre du Plan d'incitation 2022 d'Olema.
Les options d'achat d'actions ont une durée de 10 ans et un prix d'exercice de 16,46 $ par action, égal au dernier prix de vente signalé au 1er août 2024. Elles sont acquises sur quatre ans, avec 25 % acquises à l'anniversaire et le reste en 36 versements mensuels égaux, sous réserve d'un emploi continu. Cette attribution est conforme à la Règle de cotation Nasdaq 5635(c)(4) en tant qu'incitation pour les nouveaux employés.
Olema Oncology (Nasdaq: OLMA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf zielgerichtete Therapien für Frauenkrebserkrankungen spezialisiert hat, hat die Gewährung von Aktienoptionen an zwei neuen Mitarbeitern bekannt gegeben. Die Optionen erlauben den Kauf von 11.800 Aktien des Unternehmens, gültig ab dem 1. August 2024. Diese Auszeichnungen wurden vom Vergütungsausschuss genehmigt und im Rahmen des 2022 Induktionsplans von Olema vergeben.
Die Aktienoptionen haben eine Laufzeit von 10 Jahren und einen Ausübungspreis von $16,46 pro Aktie, was dem zuletzt gemeldeten Verkaufspreis am 1. August 2024 entspricht. Sie werden über vier Jahre fällig, wobei 25% am ersten Jahrestag fällig werden und der Rest in 36 gleichen monatlichen Raten, vorbehaltlich einer kontinuierlichen Anstellung. Diese Gewährung erfolgt gemäß der Nasdaq-Gelisteten Regel 5635(c)(4) als Anreiz für neue Mitarbeiter.
- Olema Oncology is attracting new talent, potentially strengthening its workforce
- The company's stock price is $16.46 per share, indicating market valuation
- Potential dilution of existing shareholders' equity due to new stock option grants
SAN FRANCISCO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the Company granted stock options to two new employees to purchase an aggregate of 11,800 shares of the Company's common stock, effective as of August 1, 2024. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan, with a grant date of August 1, 2024, as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of
Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for women living with cancer. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. In addition to our lead product candidate, palazestrant (OP-1250), a proprietary, orally-available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at www.olema.com.
Contact:
Geoffrey Mogilner, Investor Relations and Communications
ir@olema.com
FAQ
How many new employees received stock options from Olema Oncology (OLMA) on August 1, 2024?
What is the total number of shares granted in stock options by Olema Oncology (OLMA) on August 1, 2024?
What is the exercise price of the stock options granted by Olema Oncology (OLMA) on August 1, 2024?
What is the vesting schedule for the stock options granted by Olema Oncology (OLMA) on August 1, 2024?
